Cronos Group Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.03B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 67.5× Cronos Group Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | REGN | |
|---|---|---|
Market Cap | $1.03B | $69.52B |
Sector | Health | Health |
52-Week High | $3.27 | $812.27 |
52-Week Low | $1.95 | $542.52 |
Enterprise Value | $211.19M | $63.47B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →